ASHLEY ZEHNDER  Founder and CEO
 

ASHLEY ZEHNDER

Founder and CEO

Ashley earned her DVM from University of Florida, completed residency training in companion exotics at UC Davis and her PhD from Stanford in Cancer Biology. She has been working at the intersection of human and animal health with a focus on translating findings from veterinary medicine and non-model organisms.

 
 
 
 
 
 

KATIE GRABEK

Founder and CSO

Katie earned her PhD in Human Medical Genetics at the University of Colorado, Anschutz Medical Campus. She next trained as a postdoctoral scholar in computational biology in Dr. Carlos Bustamante’s lab as Stanford. Her research has focused on utilizing proteomic, transcriptomic and genomic approaches to identify the molecular components underlying the highly dynamic phenotype of hibernation.

KATIE GREBEK  Founder and CSO
 
 
 
LINDA GOODMAN  Founder and CtO
 

LINDA GOODMAN

Founder and CtO

Linda earned an MPhil in Computational Biology from the University of Cambridge and her Ph.D. in Genetics and Genomics from Harvard University. She previously held positions at the Broad Institute and Stanford University studying comparative mammalian genomics and human disease genetics.

 
 

Advisors

DR. CARLOS BUSTAMANTE

Chair of the Department of Biomedical Data Science at Stanford University

DR. SANDY MARTIN

Professor of Cell and Developmental Biology at the University of Colorado, Denver

DR. MICHAEL KENT

Director Clinical trials & Oncology at the University of California, Davis

DR. ALLYSON HINDLE

Assistant Professor at Harvard University / Massachusetts General Hospital

DR. MATTHEW ANDREWS

Director of Vertebrate Genome Biology at the Broad Institute of MIT and Harvard

DR. JASON RAVENAL

Novartis Pharmaceuticals
Director, Portfolio Strategy

DR. THOMAS HUGHES

President and CSO at Navitor Pharmaceuticals

DR. ELINOR KARLSSON

Director of Vertebrate Genome Biology at the Broad Institute of MIT and Harvard